Literature DB >> 29928201

Efficacy and Tolerability of Topical Green Tea Extract (Polyphenon E) Application in a "Therapy-Resistant" Plantar Wart.

Giancarlo Meloni1, Massimo Milani2.   

Abstract

Plantar warts account for 30% of all cutaneous warts. These lesions could be very painful, especially if the lesion is located over pressure sites such as the metatarsal head. Plantar wart treatment remains a challenging therapeutic problem. A 67-year-old immunocompetent nonsmoking man presented with a large mosaic plantar wart on his right foot. The lesion had been present for 5 years. Several cryotherapy sessions (a total of 6 procedures) had been performed with no success. The lesion was therefore treated with a 5-fluorouracil (5-FU) regimen and then with a topical combination of 5-FU and salicylic acid, but also these approaches failed. At the initial visit, a large (16 cm2) mosaic wart lesion was present. Treatment with topical Polyphenon E, 10%, twice daily was prescribed and started. After 3 months of treatment, the lesion completely disappeared. Interestingly, no curettage or mechanical pickling of the hyperkeratotic parts of the lesion were performed before the start of the treatment. Local tolerability was evaluated as very good by the patient.

Entities:  

Keywords:  Case report; Green tea extract; Sinecatechins; Warts

Year:  2018        PMID: 29928201      PMCID: PMC6006655          DOI: 10.1159/000489160

Source DB:  PubMed          Journal:  Case Rep Dermatol        ISSN: 1662-6567


Introduction

Plantar warts are a common viral skin disease caused by human papillomavirus (HPV) infection [1]. HPV has a specific tropism for squamous stratified epithelium [2] and this infection leads to proliferation of keratinocytes. HPV infection is characterized by a relevant immune evasion mechanism that inhibits and delays the host immune response to the virus [3]. HPV genotypes types 2, 4, 27, 57, and 60 are responsible for common and plantar warts and myrmecia [4]. On the other hand, genotypes 6 and 11 are the most common HPV involved in genital wart [5] development. Curettage, topical salicylic acid, and cryotherapy are often used in plantar warts [6]. Liquid nitrogen is the most frequently used treatment for this type of warts; however, this procedure is in general very painful [7]. Excision is not a good option owing to frequent recurrences or scarring [8]. In case of therapy-resistant lesions, laser and photodynamic therapy approaches could be used [9] but these methods are time- and cost-consuming. Therefore, in case of plantar warts, both first- and second-line treatments are in general still unsatisfactory due to their low efficacy, low local tolerability, and high recurrence rate [10]. Topical green tea extract containing catechins (Polyphenon E) is indicated as a first-line treatment for genital warts (condylomata acuminata) [11]. In subjects with genital warts, Polyphenon E, applied 3 times a day and up to 16 weeks, induced a complete clearance rate in more than 50% of patients [12]. In addition, the recurrence rate at 3 months after the conclusion of the therapy is as low as < 6% [9]. Polyphenon E is a quantified extract of green tea leaves (Camellia sinensis) where the main active substance is epigallocatechin gallate (EGCG), a polyphenol substance which represents the major component of the catechins fraction [13]. EGCG has potent anti-inflammatory, antioxidant, and proapoptotic actions. These mechanisms could explain its antiviral properties [14]. Recent data have shown that EGCG is able to modulate the cellular genes involved in Toll-like receptor production and in the apoptosis mechanisms [15]. The product has shown a good safety and tolerability profile. Local skin reactions like erythema and edema, in general mild to moderate, have been reported in most treated subjects [16]. Polyphenon E has shown to be an effective and very well-tolerated treatment for common [17] and plane [18] warts. Data regarding the efficacy of Polyphenon E in plantar warts are lacking so far. We report the clinical efficacy and the tolerability of Polyphenon E 10% ointment (VeregenTM, Medigene, Germany) in a subject with a “difficult-to-treat”, treatment-resistant plantar wart.

Case Description

A 67-year-old immunocompetent nonsmoking man presented with a large mosaic plantar wart on his right foot. The lesion had been present for 5 years. Several cryotherapy sessions (a total of 6 procedures) had been performed with no success. The lesion was therefore treated with a 5-fluorouracil regimen and then with a topical combination of 5-fluorouracil and salicylic acid, but also these approaches failed. At the initial visit, a large (16 cm2) mosaic wart lesion was present (Fig. 1). Treatment with topical Polyphenon E 10% twice daily was prescribed and started. After 3 months of treatment, the lesion completely disappeared (Fig. 2). Interestingly, no curettage or mechanical pickling of the hyperkeratotic parts of the lesion were performed before the start of the treatment. Local tolerability was evaluated as very good by the patient.
Fig. 1.

Plantar mosaic wart lesion on the right foot before treatment with green tea extract.

Fig. 2.

Plantar region after a 3-month treatment with green tea extract.

Discussion

Plantar warts account for 30% of all cutaneous warts [19]. Large lesions are in general plaques with rough hyperkeratotic surface with some brown-black dots representing thrombosed capillaries [20]. These lesions could be very painful, especially if the lesion is located over pressure sites such as the metatarsal head [21]. Plantar wart treatment remains a challenging therapeutic problem [22]. Some procedures could be very painful with a long downtime posttreatment period [23]. Polyphenon E ointment is considered an effective, well-tolerated, self-applicable topical treatment of genital warts [24]. Clinical efficacy and tolerability was evaluated in randomized vehicle-controlled phase III trials in more than 1,000 patients [25]. Complete clearance rate is observed in 51% of the treated subjects. Mean treatment duration for complete clearance was between 14 and 16 weeks [26]. Polyphenon E has an antiviral action trough pathway triggering cell growth arrest and increasing proapoptotic molecules like p53 and p16 [27]. In addition, this compound interferes with cellular activity of E6 and E7, two HPV virus proteins [28]. E6 and E7are involved in the process of apoptosis inhibition and in the immune evasion mechanisms [29]. Therefore, Polyphenon E could express anti-HPV action through multiple mechanisms. The gene modulation expressed by Polyphenon could be of help in fighting therapy-resistant HPV lesions. Polyphenon E has shown to be an effective treatment of plane warts of the face [30]. An ideal wart therapy should be easy to apply (preferably home-based), painless, able to resolve all the treated lesions, not causing scarring, and with no or very short downtime period [23]. In this case report, we have shown a high clinical efficacy of Polyphenon E in the treatment of a therapy-resistant large mosaic plantar wart lesion. It is remarkable that complete clearance of the lesion was achieved with a 12-week treatment without any pretreatment curettage or pickling procedures and without a downtime period and without scar formation. This case report suggests that topical Polyphenon E 10% could be an effective therapeutic strategy in subjects with “difficult-to-treat” plantar wart lesions. Specific controlled trials in this specific population are warranted.

Statement of Ethics

The authors have no ethical conflicts to disclose.

Disclosure Statement

M.M. is an employee of Cantabria Labs Difa Cooper; Caronno P., Italy.
  27 in total

Review 1.  Immune evasion in human papillomavirus-associated cervical cancer.

Authors:  Robert W Tindle
Journal:  Nat Rev Cancer       Date:  2002-01       Impact factor: 60.716

2.  Guidelines for the management of cutaneous warts.

Authors:  J C Sterling; S Handfield-Jones; P M Hudson
Journal:  Br J Dermatol       Date:  2001-01       Impact factor: 9.302

3.  Antioxidant chemistry of green tea catechins. Identification of products of the reaction of (-)-epigallocatechin gallate with peroxyl radicals.

Authors:  S Valcic; A Muders; N E Jacobsen; D C Liebler; B N Timmermann
Journal:  Chem Res Toxicol       Date:  1999-04       Impact factor: 3.739

Review 4.  Management of genital warts.

Authors:  Charles M Kodner; Soraya Nasraty
Journal:  Am Fam Physician       Date:  2004-12-15       Impact factor: 3.292

5.  Seroepidemiological studies of human papilloma virus (HPV-1) infections.

Authors:  H Pfister; H zur Hausen
Journal:  Int J Cancer       Date:  1978-02-15       Impact factor: 7.396

6.  Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines.

Authors:  M Masuda; M Suzui; I B Weinstein
Journal:  Clin Cancer Res       Date:  2001-12       Impact factor: 12.531

Review 7.  Treatment of Warts in Children: An Update.

Authors:  P Gerlero; Á Hernández-Martín
Journal:  Actas Dermosifiliogr       Date:  2016-05-27

Review 8.  Human papillomavirus-associated tumors of the skin and mucosa.

Authors:  S Majewski; S Jablonska
Journal:  J Am Acad Dermatol       Date:  1997-05       Impact factor: 11.527

Review 9.  Cutaneous warts: an evidence-based approach to therapy.

Authors:  Rocky Bacelieri; Sandra Marchese Johnson
Journal:  Am Fam Physician       Date:  2005-08-15       Impact factor: 3.292

10.  Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial.

Authors:  Silvio Tatti; James M Swinehart; Claus Thielert; Hoda Tawfik; Axel Mescheder; Karl R Beutner
Journal:  Obstet Gynecol       Date:  2008-06       Impact factor: 7.661

View more
  1 in total

Review 1.  Applications of a Standardized Green Tea Catechin Preparation for Viral Warts and Human Papilloma Virus-Related and Unrelated Cancers.

Authors:  Noriyuki Miyoshi; Hiroki Tanabe; Takuji Suzuki; Koichi Saeki; Yukihiko Hara
Journal:  Molecules       Date:  2020-06-02       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.